| HOME >> BIOLOGY >> TECHNOLOGY |
LA JOLLA, Calif., July 29 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) announced today that it has received a Therapeutics Development Initiative award from The Michael J. Fox Foundation for Parkinson's Research. The program targets industry-based research with potential to fundamentally alter the course of Parkinson's disease (PD) treatment. In collaboration with Dr. Christopher Ross of Johns Hopkins University, Zenobia will discover and develop compounds that block the activity of LRRK2, a protein that is believed to be overactive in PD patients. The goal is to preserve brain function by stopping the effects of the overactivity. If successful, the work could lead to a neuroprotective treatment for PD with potential to slow or stop the course of the disease -- something no currently available therapy has been proven to do. Current treatments alleviate the symptoms but do not attack the underlying disease, or alter its course.
Zenobia will use its fragment-based lead discovery (FBLD) expertise to
discover compounds that bind to LRRK2. FBLD is a proven drug discovery
approach where fragments of drugs are screened for ability to bind to a
target. Fragments will be visualized bound to LRRK2 and evolved into
compounds that block its activity. These compounds will be tested for their
ability to protect neurons in cell culture, and to reverse effects of the
overactive protein in animal models. "I believe Zenobia's methods represent
a unique and tremendously exciting approach to drug discovery," said
Christopher A. Ross, M.D., Ph.D, Professor of Psychiatry, Neurology and
Neuroscience at Johns Hopkins University, and chair of Zenobia's Scientific
Advisory Board. "The fragment-based screening method has the potential to
identify and develop novel compounds not present in the libraries of large
pharmaceutical companies. It also is more likely to identify small ligands
with a better chance of good penetration into the brain, making it
especially suitable
'/>"/>
| SOURCE Zenobia Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |